ARCHIVES

Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Cancer.gov Knocked Offline By Theft Of Routers

July 11, 2003

NCI Seeks CRADA Partners To Develop Targets Drugs

October 24, 1997

Ovarian Cancer Symptom Indices May Need to be Re-Evaluated

January 27, 2012

DeVita Resigns As No. 2 At Sloan-Kettering To “Pursue Clinical Research,” Hospital Says

May 31, 1991

FASEB Report On NIH Funding Urges Sustained Growth In Fiscal Year 2011

April 16, 2010

Nomograms 66% Correct In Predicting Outcome For Brachytherapy, Study Finds

September 28, 2001